Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Niels Jongs's publication output changed over time?
ScholarIQpublication output · 2020–2026
Output declined50% over the shown period — from 2 works in 2020 to 1 in 2026.
2
5
1
2
1
20202021202220242026
What are the most-cited papers on Niels Jongs?
ScholarIQmost cited works
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
David C. Wheeler, Bergur V. Stefánsson, Niels Jongs, Glenn M. Chertow, Tom Greene, Fan Fan Hou, John J.V. McMurray, Ricardo Correa‐Rotter, Peter Rossing, Robert D. Toto, C. David Sjöström, Anna Maria Langkilde, Hiddo J.L. Heerspink
The Lancet Diabetes & Endocrinology. 2020535 CitationsOPEN ACCESS
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
David C. Wheeler, Robert D. Toto, Bergur V. Stefánsson, Niels Jongs, Glenn M. Chertow, Tom Greene, Fan Fan Hou, John J.V. McMurray, Roberto Pecoits‐Filho, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Kausik Umanath, Anna Maria Langkilde, Hiddo J.L. Heerspink
Kidney International. 2021404 CitationsOPEN ACCESS
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Niels Jongs, Tom Greene, Glenn M. Chertow, John J.V. McMurray, Anna Maria Langkilde, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink
The Lancet Diabetes & Endocrinology. 2021213 CitationsOPEN ACCESS
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Hiddo J.L. Heerspink, Niels Jongs, Glenn M. Chertow, Anna Maria Langkilde, John J.V. McMurray, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Robert D. Toto, David C. Wheeler, Tom Greene
The Lancet Diabetes & Endocrinology. 2021199 CitationsOPEN ACCESS
Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial
Michele Provenzano, María Jesús Puchades, Carlo Garofalo, Niels Jongs, Luis D’Marco, Michele Andreucci, Luca De Nicola, José Luis Górriz, Hiddo J.L. Heerspink
Journal of the American Society of Nephrology. 2022183 CitationsOPEN ACCESS
Related on ScholarIQ
University Medical Center Groningen
Institution
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
Paper
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
Paper
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Paper
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Paper
Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial
Paper